Ocular photodynamic therapy
This article was originally published in The Gray Sheet
Coverage review initiated by HCFA July 26 could lead to a national Medicare coverage decision for QLT PhotoTherapeutics' Visudyne (verteporfin) to treat age-related macular degeneration (AMD). Marketed by Novartis' Ciba Vision eye care unit, Visudyne is an intravenous photosensitizing drug that is activated by a laser. Coherent, Inc. and Zeiss Humphrey Systems have competed in the AMD laser market since Visudyne's FDA approval April 13
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.